Summary of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Ratings on May 16, 2018

May 16, 2018 - By Michele Cranor

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Ratings Coverage

In total 8 analysts cover CymaBay Therapeutics (NASDAQ:CBAY). “Buy” rating has 8, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 16 are the (NASDAQ:CBAY)’s analyst reports since November 28, 2017 according to StockzIntelligence Inc. On Tuesday, November 28 the company was maintained by Leerink Swann. On Wednesday, May 9 the company was maintained by Oppenheimer. On Wednesday, January 24 the company was maintained by H.C. Wainwright. On Wednesday, March 28 the firm earned “Buy” rating by H.C. Wainwright. On Wednesday, April 11 the rating was maintained by Leerink Swann with “Buy”. On Thursday, March 15 the firm earned “Buy” rating by Piper Jaffray. On Wednesday, March 21 the company was maintained by Oppenheimer. On Friday, March 16 the stock has “Buy” rating by Cantor Fitzgerald. On Wednesday, January 31 the firm has “Buy” rating given by Piper Jaffray. On Wednesday, March 28 the rating was maintained by Leerink Swann with “Buy”. Listed here are CymaBay Therapeutics, Inc. (NASDAQ:CBAY) PTs and latest ratings.

09/05/2018 Broker: Oppenheimer Rating: Buy New Target: $20.0000 Maintain
16/04/2018 Broker: Roth Capital Rating: Buy New Target: $27.0000 Maintain
11/04/2018 Broker: Leerink Swann Rating: Buy New Target: $20.0000 Maintain
11/04/2018 Broker: Evercore Rating: Buy
28/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $18.0000 Initiate
28/03/2018 Broker: Leerink Swann Rating: Buy New Target: $16.0000 Maintain
21/03/2018 Broker: Oppenheimer Rating: Buy Maintain
16/03/2018 Broker: SunTrust Rating: Buy New Target: $19.0 Maintain
16/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $16.0 Maintain
15/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $16.0 Maintain

CBAY is reaching $12.21 during the last trading session, after increased 3.83%.CymaBay Therapeutics, Inc. has 1.07M shares volume, 0.83% up from normal. CBAY is uptrending and has moved 197.77% since May 16, 2017. CBAY outperformed the S&P500 by 186.22%.

CymaBay Therapeutics Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases.The firm is valued at $717.57 million. It engages in developing seladelpar , a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout.Last it reported negative earnings. The companyÂ’s product candidate also includes MBX-2982, an oral G-protein coupled receptor agonist to treat type II diabetes.

For more CymaBay Therapeutics, Inc. (NASDAQ:CBAY) news brought out briefly go to: Nasdaq.com, Seekingalpha.com, Globenewswire.com, Streetinsider.com or Nasdaq.com. The titles are as follows: “Report: Developing Opportunities within CymaBay Therapeutics, IAC/InterActiveCorp, Axcelis Technologies, La Quinta …” brought out on April 20, 2018, “CymaBay Makes Progress With Seladelpar” on April 30, 2018, “CymaBay to Report First Quarter 2018 Financial Results on Tuesday, May 8” with a publish date: May 01, 2018, “Omega’s 13F Shows Increase in Ocwen (OCN), Synchrony (SYF), United (UAL), Exits Zynga (ZNGA) (More…)” and the last “CymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic …” with publication date: May 08, 2018.

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.